

## Special Issue

# Hyperthermia-based Anticancer Treatments

### Message from the Guest Editors

Hyperthermia—an adjuvant anti-cancer treatment using temperatures exceeding the physiologically optimal level—affects cells and tissues in various ways. For several decades it has been successfully applied for treatment of many tumour types, including recurrent breast cancer, cervical carcinoma, head & neck cancer and melanoma. Hyperthermia affects multiple intracellular processes, DNA repair pathways, as well as systemic immune responses. Furthermore, it can target cancer cells in hypoxic and nutrient-deprived tumour areas where ionising radiation and chemotherapy are least effective. Hyperthermia can also modify factors that are essential for tumour survival and growth. Thus, the effects of hyperthermia are multifactorial. Hyperthermia is a clinically proven successful adjuvant treatment. As such in this Special Issue of *Cancers* we aim to increase awareness of the benefits of hyperthermia to a broader audience and to discuss all novel preclinical and clinical aspects of hyperthermia-based anticancer treatments and welcome contributions to this theme.

---

### Guest Editors

Dr. Nicolaas A.P. Franken

Dr. Arlene L. Oei

Dr. Johannes Crezee

---

### Deadline for manuscript submissions

closed (31 March 2020)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/18744](https://mdpi.com/si/18744)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)